Product image of Nexavar (Sorafenib) supplied by GNH India

Nexavar

Active Ingredient:
Sorafenib
Origin:
EU

Nexavar (Sorafenib)

Sorafenib, the active ingredient in Nexavar, is a tyrosine kinase inhibitor presented as a 200 mg tablet for oral use. It treats advanced renal cell carcinoma, hepatocellular carcinoma, and radioiodine‑refractory differentiated thyroid carcinoma in adult patients.

GNH India supplies Nexavar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Sorafenib is a multi‑kinase inhibitor used in oncology for specific solid tumours.
  • Advanced renal cell carcinoma: prolongs progression‑free and overall survival in adult patients.
  • Hepatocellular carcinoma: improves survival in patients with unresectable disease.
  • Radioiodine‑refractory differentiated thyroid carcinoma: delays disease progression in adults.

How It Works

  • Sorafenib inhibits multiple intracellular kinases including Raf serine/threonine kinases, vascular endothelial growth factor receptors (VEGFR‑1,‑2,‑3), platelet‑derived growth factor receptors (PDGFR‑α/β), FLT‑3 and c‑KIT. By blocking these pathways it reduces tumor cell proliferation, angiogenesis, and metastatic potential, leading to antitumour activity across several solid tumours. The combined inhibition of the RAF/MEK/ERK cascade and angiogenic signalling disrupts both tumor growth and its blood supply.

Side Effects

Sorafenib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Diarrhea: frequent loose stools.
  • Fatigue: persistent tiredness.
  • Hand‑foot skin reaction: redness, swelling or pain on palms and soles.
  • Hypertension: elevated blood pressure.
  • Nausea: feeling of sickness.

Serious or Rare Side Effects

  • Cardiac ischemia or infarction: chest pain or heart attack.
  • Severe hepatic dysfunction: jaundice, elevated liver enzymes.
  • Gastrointestinal perforation: severe abdominal pain and infection.

Precautions & Warnings

When prescribing Sorafenib, clinicians should consider several safety precautions.

  • Baseline assessment: obtain liver function tests and blood pressure before starting therapy.
  • Cardiovascular monitoring: regularly check blood pressure and ECG for signs of ischemia.
  • Dermatologic evaluation: monitor for severe hand‑foot skin reaction and rash.
  • Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
  • Pregnancy and lactation: avoid use in pregnant or breastfeeding women due to unknown risk.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Avoid Interactions

Sorafenib interacts with several medicines through metabolic pathways and pharmacodynamic effects.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce sorafenib exposure.
  • Anticoagulants (warfarin, direct oral anticoagulants): increased bleeding risk.
  • QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (ketoconazole, clarithromycin): may increase sorafenib levels.
  • St. John’s wort: potential reduction in efficacy.
  • Antihypertensives: may require dose adjustment due to sorafenib‑induced hypertension.

Frequently Asked Questions

Nexavar (generic name Sorafenib) is prescribed for adult patients with advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and radioiodine‑refractory differentiated thyroid carcinoma. It belongs to the class of tyrosine kinase inhibitors and works by targeting pathways that drive tumor growth and blood vessel formation.

Sorafenib blocks multiple kinases involved in tumor cell signaling, including Raf, VEGFR, PDGFR, FLT‑3 and c‑KIT. Inhibiting these enzymes reduces cancer cell proliferation, limits new blood‑vessel formation (angiogenesis), and interferes with metastatic processes, thereby exerting antitumor effects.

The specific dose and schedule of Nexavar are determined by the treating physician based on the patient’s condition, weight, liver function, and other clinical factors. Prescribers follow approved labeling and adjust the regimen as needed for safety and efficacy.

Safety data for Sorafenib in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It is generally avoided in pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out.

To request Nexavar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Sorafenib in many indications is sunitinib, another multi‑kinase inhibitor. While both target angiogenic pathways, they differ in kinase selectivity, side‑effect profiles, and dosing schedules. Choice between them depends on individual patient factors, tolerability, and physician judgment.

Nexavar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Nexavar is taken orally as a tablet, usually with a glass of water. It is swallowed whole and should be taken exactly as prescribed, without crushing or chewing, unless the prescriber provides specific instructions.

Serious risks include cardiac events such as ischemia or infarction, severe liver toxicity manifested by jaundice or markedly elevated enzymes, and gastrointestinal perforation. Patients should be monitored regularly for these conditions and advised to report any concerning symptoms promptly.

Nexavar is contraindicated in patients with known hypersensitivity to sorafenib or any of its excipients. It should also be avoided in individuals with uncontrolled hypertension, recent major cardiovascular events, or severe hepatic impairment, unless a specialist determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sorafenib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT